News & Updates

Show Multimedia Only

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

12 Jun 2026 by

Immunotherapy directed at desmocollin-3 (DSC3) safely improves outcomes in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) expressing DSC3, reports a study presented at ASCO 2026.

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

12 Jun 2026

RSV tied to increased childhood asthma risk

12 Jun 2026 by

A study presented at ESPID 2026 demonstrates an association between respiratory syncytial virus (RSV) infection and an increased risk of childhood asthma.

RSV tied to increased childhood asthma risk

12 Jun 2026

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

12 Jun 2026

Administering influenza vaccine concomitantly with pertussis-containing vaccine during pregnancy does not contribute to increased risk of adverse pregnancy outcomes, as reported in a retrospective study.

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

12 Jun 2026

Original New Drug Application Approvals by US FDA (16-31 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 16-31 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2026)

12 Jun 2026

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

11 Jun 2026

High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

11 Jun 2026

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

11 Jun 2026 by

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

11 Jun 2026

Scoring system predicts postoperative complication in IPF patients with NSCLC

11 Jun 2026

A novel scoring system has shown its capacity in predicting postoperative pulmonary complications in patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF), reports a study.

Scoring system predicts postoperative complication in IPF patients with NSCLC

11 Jun 2026

Aldosterone production ups kidney failure, MACE risks in adults with hypertension

11 Jun 2026 by

Kidney function may rapidly decline in adults with hypertension and renin-independent aldosterone production, reveals a study. Furthermore, those with higher aldosterone-to-renin ratio (ARR) levels are at increased risk of kidney failure and major adverse cardiovascular events (MACE).

Aldosterone production ups kidney failure, MACE risks in adults with hypertension

11 Jun 2026

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

11 Jun 2026 by

Adding low-dose pembrolizumab to chemotherapy results in significant improvements in overall (OS) and progression-free survival (PFS) among patients with advanced non-small cell lung cancer (NSCLC), as shown in a phase 3 trial presented at ASCO 2026.

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

11 Jun 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

DSC3-targeted immunotherapy shows promise in recurrent/metastatic HNSCC

RSV tied to increased childhood asthma risk

RSV tied to increased childhood asthma risk

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

Flu vax may be safely co-administered with pertussis-containing vaccine during pregnancy

Original New Drug Application Approvals by US FDA (16-31 May 2026)

Original New Drug Application Approvals by US FDA (16-31 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Scoring system predicts postoperative complication in IPF patients with NSCLC

Scoring system predicts postoperative complication in IPF patients with NSCLC

Aldosterone production ups kidney failure, MACE risks in adults with hypertension

Aldosterone production ups kidney failure, MACE risks in adults with hypertension

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC

Low-dose pembrolizumab plus chemo prolongs survival in advanced NSCLC